Tardive Dyskinesia Treatment | AUSTEDO XR® (deutetrabenazine)
Reduce involuntary movements with AUSTEDO XR® (deutetrabenazine) tablets treatment for TD. See safety info and boxed warning.
Tardive Dyskinesia (TD) | AUSTEDO XR® (deutetrabenazine) …
AUSTEDO XR ® (deutetrabenazine) extended-release tablets and AUSTEDO ® (deutetrabenazine) tablets are indicated in adults for the treatment of chorea associated with Huntington’s disease and …
Austedo (deutetrabenazine): Uses, Side Effects, Dosage Guide
Aug 20, 2025 · Austedo's drug class is a VMAT2 inhibitor (vesicular monoamine transporter 2 inhibitor). Austedo tablets are taken twice daily, and the Austedo XR (extended-release) tablets are taken once …
Patients Taking AUSTEDO XR® (deutetrabenazine) - GlobeNewswire
Sep 21, 2025 · AUSTEDO XR and AUSTEDO® are the first vesicular monoamine transporter 2 (VMAT2) inhibitors approved by the U.S. Food and Drug Administration in adults for the treatment of …
FDA Approves One Pill, Once-Daily Tablets of Deutetrabenazine for ...
May 30, 2024 · The FDA has approved a new one-pill, once-daily tablet administration option for deutetrabenazine (Austedo XR; Teva Pharmaceuticals), a medication for tardive dyskinesia and …
The dose of deutetrabenazine (Austedo) is determined individually for each patient based on reduction of chorea or tardive dyskinesia and tolerability. The package insert contains specific dosing …
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR ...
Nov 7, 2025 · The findings demonstrate that treatment with AUSTEDO (deutetrabenazine) tablets or AUSTEDO XR (deutetrabenazine) extended-release tablets for tardive dyskinesia (TD) led to …
Austedo XR Approved: A New Treatment Option for Tardive Dyskinesia …
May 30, 2024 · The US Food and Drug Administration (FDA) has approved Teva Pharmaceuticals’ Austedo XR (deutetrabenazine) as a once-daily pill treatment option, available in 4 new tablet …
Austedo: Package Insert / Prescribing Information / MOA - Drugs.com
Mar 9, 2025 · The efficacy of AUSTEDO in the treatment for tardive dyskinesia was established in two 12‑week, randomized, double-blind, placebo-controlled, multi-center trials conducted in 335 adult …
Teva Pharmaceutical Industries Ltd. - Teva Announces AUSTEDO® XR ...
May 29, 2024 · AUSTEDO XR (deutetrabenazine) extended-release tablets and AUSTEDO ® (deutetrabenazine) tablets are indicated in adults for the treatment of chorea associated with …